ZIOPHARM Oncology, Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in ZIOPHARM Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZIOP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
ZIOPHARM Oncology stock price (NASDAQ: ZIOP)Use our graph to track the performance of ZIOP stocks over time.
ZIOPHARM Oncology shares at a glance
|Latest market close||$3.03|
|52-week range||$2.06 - $5.95|
|50-day moving average||$2.57|
|200-day moving average||$3.48|
|Wall St. target price||$5.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.58|
Buy ZIOPHARM Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy ZIOPHARM Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ZIOPHARM Oncology price performance over time
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||14.77%|
|3 months (2021-05-05)||3.03|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
ZIOPHARM Oncology financials
|Gross profit TTM||$-52,696,000|
|Return on assets TTM||-31.62%|
|Return on equity TTM||-58.21%|
|Market capitalisation||$484.9 million|
TTM: trailing 12 months
Shorting ZIOPHARM Oncology shares
There are currently 35.7 million ZIOPHARM Oncology shares held short by investors – that's known as ZIOPHARM Oncology's "short interest". This figure is 1.3% up from 35.2 million last month.
There are a few different ways that this level of interest in shorting ZIOPHARM Oncology shares can be evaluated.
ZIOPHARM Oncology's "short interest ratio" (SIR)
ZIOPHARM Oncology's "short interest ratio" (SIR) is the quantity of ZIOPHARM Oncology shares currently shorted divided by the average quantity of ZIOPHARM Oncology shares traded daily (recently around 1.7 million). ZIOPHARM Oncology's SIR currently stands at 20.43. In other words for every 100,000 ZIOPHARM Oncology shares traded daily on the market, roughly 20430 shares are currently held short.
However ZIOPHARM Oncology's short interest can also be evaluated against the total number of ZIOPHARM Oncology shares, or, against the total number of tradable ZIOPHARM Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ZIOPHARM Oncology's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 ZIOPHARM Oncology shares in existence, roughly 170 shares are currently held short) or 0.2002% of the tradable shares (for every 100,000 tradable ZIOPHARM Oncology shares, roughly 200 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ZIOPHARM Oncology.
Find out more about how you can short ZIOPHARM Oncology stock.
ZIOPHARM Oncology share dividends
We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.
Have ZIOPHARM Oncology's shares ever split?
ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.
ZIOPHARM Oncology share price volatility
Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $2.06 up to $5.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 2.0098. This would suggest that ZIOPHARM Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ZIOPHARM Oncology overview
ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.
Stocks similar to ZIOPHARM Oncology
ZIOPHARM Oncology in the news
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
Equitec Proprietary Markets, Llc Buys Kansas City Southern, African Gold Acquisition Corp, Coherent Inc, Sells Amazon.com Inc, Industrial Select Sector SPDR, SPDR Dow Jones Industrial Average ETF
Frequently asked questionsWhat percentage of ZIOPHARM Oncology is owned by insiders or institutions?
Currently 9.487% of ZIOPHARM Oncology shares are held by insiders and 59.69% by institutions. How many people work for ZIOPHARM Oncology?
Latest data suggests 103 work at ZIOPHARM Oncology. When does the fiscal year end for ZIOPHARM Oncology?
ZIOPHARM Oncology's fiscal year ends in December. Where is ZIOPHARM Oncology based?
ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129 What is ZIOPHARM Oncology's ISIN number?
ZIOPHARM Oncology's international securities identification number is: US98973P1012 What is ZIOPHARM Oncology's CUSIP number?
ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101
More guides on Finder
How to buy Chobani stock when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Stronghold Digital Mining (SDIG) stock when it goes public
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
How to buy ROX Financial LP (ROXA) stock when it goes public
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
Ask an Expert